Lilly Sues Teva To Block Generic Symbyax

Law360, New York (April 27, 2005, 12:00 AM EDT) -- Eli Lilly and Co. has filed a lawsuit to bar Israeli drug maker Teva Pharmaceutical Industries Ltd. from marketing a generic version of the anti-psychotic drug Symbyax.

Teva is seeking U.S. Food and Drug Administration (FDA) approval to sell a low-cost version of bipolar depression treatment Symbyax, which combines ingredients from Lilly's Zyprexa schizophrenia medicine and Prozac antidepressant.

The FDA lists the filing of an Abbreviated New Drug Application (ANDA) for generic Symbyax on January 10, 2005, according to the agency’s website.

In its complaint, filed...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.